| __timestamp | Eli Lilly and Company | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 14993000000 |
| Thursday, January 1, 2015 | 6533000000 | 14247000000 |
| Friday, January 1, 2016 | 6452000000 | 14192000000 |
| Sunday, January 1, 2017 | 6588100000 | 14997000000 |
| Monday, January 1, 2018 | 5975100000 | 16471000000 |
| Tuesday, January 1, 2019 | 6213800000 | 14369000000 |
| Wednesday, January 1, 2020 | 6121200000 | 14197000000 |
| Friday, January 1, 2021 | 6431600000 | 14886000000 |
| Saturday, January 1, 2022 | 6440400000 | 14253000000 |
| Sunday, January 1, 2023 | 6941200000 | 12489000000 |
| Monday, January 1, 2024 | 8593800000 | 12566000000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, managing operational costs is crucial for maintaining profitability. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants, Eli Lilly and Company and Novartis AG, from 2014 to 2023. Over this period, Novartis consistently reported higher SG&A expenses, averaging around 14.5 billion USD annually, nearly double that of Eli Lilly's average of 6.4 billion USD. However, a notable shift occurred in 2023 when Eli Lilly's expenses surged by approximately 8%, reaching their highest at 6.9 billion USD, while Novartis saw a significant reduction of 16%, dropping to 12.5 billion USD. This trend highlights the dynamic nature of cost management strategies within the sector, reflecting broader shifts in corporate priorities and market conditions.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Novartis AG and Alnylam Pharmaceuticals, Inc.
Comparing SG&A Expenses: Novartis AG vs Insmed Incorporated Trends and Insights
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Selling, General, and Administrative Costs: Novartis AG vs Walgreens Boots Alliance, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Verona Pharma plc
SG&A Efficiency Analysis: Comparing Novartis AG and ADMA Biologics, Inc.
Selling, General, and Administrative Costs: Novartis AG vs Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Evotec SE